Checkpoint Inhibitor-Treated Merkel Cell Carcinoma With Cytokeratin 20 (CK20)-Negative Metastatic Immunophenotypic Divergence: Diagnostic and Therapeutic Implications
Diego Berlingeri Collazo, Lester Cintron Perez, Emmanuel Torres Troche, Sanjay Vora · 2026
Read Checkpoint Inhibitor-Treated Merkel Cell Carcinoma With Cytokeratin 20 (CK20)-Negative Metastatic Immunophenotypic Divergence: Diagnostic and Therapeutic Implications by Diego Berlingeri Collazo, Lester Cintron Perez, Emmanuel Torres Troche, Sanjay Vora (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13623267.txt.
Description
Diego Berlingeri Collazo and three co-authors describe a skin cancer that changed its identity papers after immunotherapy. Their case report appeared in twenty twenty-six. Merkel cell carcinoma usually stains positive for the marker CK20, a signature pathologists lean on.
The patient, a woman in her eighties, first had surgery and radiation for an arm tumor. Node recurrence brought dissection, then a checkpoint inhibitor drug. A year later, liver and lung lesions appeared. The liver biopsy read as a fast-growing neuroendocrine cancer with CK20 missing entirely. Standard chemotherapy for such tumors failed to slow it, and she moved to hospice care. The authors warn that treatment can strip the classic marker, so history must guide diagnosis.
Catalog record
| CREATOR | Diego Berlingeri Collazo, Lester Cintron Perez, Emmanuel Torres Troche, Sanjay Vora |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |